Elevated calprotectin in patients with atrial fibrillation with and without heart failure

References

• Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837–47.
   PubMed Web of Science ®Google Scholar
• Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599–610.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL. Inflammation, immunity and development of essential hypertension. J Hypertens 2014;32:228–9.
   PubMed Web of Science ®Google Scholar
• Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, Darbar D. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010;7:438–44.
   PubMed Web of Science ®Google Scholar
• Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006–10.
   PubMed Web of Science ®Google Scholar
• Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T, Moriyama Y, Miyahara K. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 2004;45:441–5.
   PubMedGoogle Scholar
• Gedikli O, Dogan A, Altuntas I, Altinbas A, Ozaydin M, Akturk O, Acar G. Inflammatory markers according to types of atrial fibrillation. Int J Cardiol 2007;120:193–7.
   PubMed Web of Science ®Google Scholar
• Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004;344:37–51.
   PubMed Web of Science ®Google Scholar
• Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, Nie B, Jiang B. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20:1407–15.
   PubMed Web of Science ®Google Scholar
• Hessian PA, Edgeworth J, Hogg N. MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. J Leukoc Biol 1993;53:197–204.
   PubMed Web of Science ®Google Scholar
• Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007;81:28–37.
   PubMed Web of Science ®Google Scholar
• Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K, Sakuma M, Shi C, Zago AC, Garasic J, Damokosh AI, Dowie TL, Poisson L, Lillie J, Libby P, Ridker PM, Simon DI. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006;113:2278–84.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Ueda M, Ikemoto M, Naruko T, Itoh A, Tamaki S, Nohara R, Terasaki F, Sasayama S, Fujita M. Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable angina. Heart 2008;94:1002–7.
   PubMed Web of Science ®Google Scholar
• Jensen LJN, Pedersen S, Bjerre M, Mogelvang R, Jensen JS, Flyvbjerg A. Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Interv Cardiol 2010;23:123–9.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Pradhan AD, Healy AM, Buros J, McCabe CH, Libby P, Cannon CP, Braunwald E, Simon DI. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 2008;155:49–55.
   PubMed Web of Science ®Google Scholar
• Ionita MG, Catanzariti LM, Bots ML, de Vries JP, Moll FL, Kwan Sze S, Pasterkamp G, de Kleijn DP. High myeloid-related protein: 8/14 levels are related to an increased risk of cardiovascular events after carotid endarterectomy. Stroke 2010;41:2010–15.
   PubMed Web of Science ®Google Scholar
• Jensen LJ, Kistorp C, Bjerre M, Raymond I, Flyvbjerg A. Plasma calprotectin levels reflect disease severity in patients with chronic heart failure. Eur J Prevent Cardiol 2012;19:999–1004.
   PubMed Web of Science ®Google Scholar
• Ma LP, Haugen E, Ikemoto M, Fujita M, Terasaki F, Fu M. S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. Int J Cardiol 2012;155:26–32.
   PubMed Web of Science ®Google Scholar
• Nilsen T, Sundstrom J, Lind L, Larsson A. Serum calprotectin levels in elderly males and females without bacterial or viral infections. Clin Biochem 2014;47:1065–8.
   PubMed Web of Science ®Google Scholar
• Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007;50:2021–8.
   PubMed Web of Science ®Google Scholar
• Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015;79:495–502.
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med 2010;123:198–204.
   PubMed Web of Science ®Google Scholar
• Kaya H, Zorlu A, Yucel H, Tatlisu MA, Kivrak T, Coskun A, Yilmaz MB. Higher cancer antigen 125 level is associated with the presence of permanent atrial fibrillation in systolic heart failure patients. Acta Cardiol 2016;71:61–6.
   PubMed Web of Science ®Google Scholar
• Yucel H, Kaya H, Zorlu A, Yildirimli K, Sancakdar E, Gunes H, Kurt R, Ozgul U, Turgut OO, Yilmaz MB. Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation. Herz 2015;40(Suppl.2):119–24.
   PubMed Web of Science ®Google Scholar
• Striz I, Trebichavsky I. Calprotectin: a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004;53:245–53.
   PubMed Web of Science ®Google Scholar
• Kerkhoff C, Klempt M, Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim Biophys Acta 1998;1448:200–11.
   PubMed Web of Science ®Google Scholar
• Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 2012;32:223–9.
   PubMed Web of Science ®Google Scholar
• Iakobishvili Z, Weissler A, Buturlin K, Goldenberg G, Strassberg B, Tur R, Hasdai D. High Sensitivity cardiac troponin T levels after elective cardioversion for atrial fibrillation/flutter. Isr Med Assoc J 2015;17:607–11.
   PubMed Web of Science ®Google Scholar
• Lund M, French JK, Johnson RN, Williams BF, White HD. Serum troponins T and I after elective cardioversion. Eur Heart J 2000;21:245–53.
   PubMed Web of Science ®Google Scholar
• Greaves K, Crake T. Cardiac troponin T does not increase after electrical cardioversion for atrial fibrillation or atrial flutter. Heart 1998;80:226–8.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Ruiz-Esquide V, Hernandez MV, Canete JD, Cabrera-Villalba SR, Ramirez J, Yague J, Sanmarti R. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford) 2015;54:2239–43.
   PubMed Web of Science ®Google Scholar
• Hansson C, Eriksson C, Alenius GM. S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res 2014;2014:696415.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Victoria Hernandez M, Ruiz-Esquide V, Raquel Cabrera-Villalba S, Ramirez J, Cuervo A, Pascal M, Yague J, Canete JD, Sanmarti R. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthrit Care Res (Hoboken) 2016;68:899–906.
   PubMed Web of Science ®Google Scholar
• Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007;49:1642–8.
   PubMed Web of Science ®Google Scholar
• Yo CH, Lee SH, Chang SS, Lee MC, Lee CC. Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis. BMJ Open 2014;4:e004418.
   Web of Science ®Google Scholar
• Galea R, Cardillo MT, Caroli A, Marini MG, Sonnino C, Narducci ML, Biasucci LM. Inflammation and C-reactive protein in atrial fibrillation: cause or effect? Tex Heart Inst J 2014;41:461–8.
   PubMed Web of Science ®Google Scholar